Verici Dx plc (AIM:VRCI)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 4.55M |
| Revenue (ttm) | 3.43M |
| Net Income (ttm) | -3.81M |
| Shares Out | 242.54M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,081 |
| Average Volume | 2,531,428 |
| Open | 1.750 |
| Previous Close | 1.875 |
| Day's Range | 1.750 - 2.000 |
| 52-Week Range | 1.000 - 8.690 |
| Beta | 1.67 |
| RSI | 44.21 |
| Earnings Date | Apr 14, 2025 |
About Verici Dx
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Cardiff, the United Kingdom. [Read more]
News
AIM Market Roundup: Ethernity Networks, Verici DX, Aferian
Ethernity Networks, Verici DX, Aferian, Coro Energy and Ascent Resources are today's biggest risers and fallers on London's AIM market
AIM Market Roundup: Rome Resources, Celadon Pharmaceuticals, Churchill China
Rome Resources, Celadon Pharmaceuticals, Churchill China, Ethernity Networks and Verici DX are today's biggest movers on London's AIM market
AIM Market Roundup: Celadon Pharma, Oracle Power, Volex
Celadon Pharmaceuticals, Oracle Power, Volex, Verici DX and Slingsby are today's biggest risers and fallers on London's AIM market
FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians
CORALVILLE, Iowa--(BUSINESS WIRE)--FBB Biomed today announced it has signed a Master Services Agreement with Verici Dx plc (AIM: VRCI.L), for Laboratory Services for Research-Use-Only (RUO) (FDA defin...